Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III Sells 3,000 Shares

Kewaunee Scientific Co. (NASDAQ:KEQU - Get Free Report) CEO Thomas David Hull III sold 3,000 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $45.63, for a total value of $136,890.00. Following the completion of the transaction, the chief executive officer now owns 37,916 shares of the company's stock, valued at approximately $1,730,107.08. This represents a 7.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Thomas David Hull III also recently made the following trade(s):

• On Friday, March 21st, Thomas David Hull III sold 213 shares of Kewaunee Scientific stock. The shares were sold at an average price of $48.53, for a total transaction of $10,336.89.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The stock was sold at an average price of $60.08, for a total transaction of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $63.01, for a total transaction of $126,020.00.

Kewaunee Scientific Stock Performance

Shares of KEQU stock traded down $2.68 during trading hours on Friday, reaching $39.82. 22,197 shares of the company's stock were exchanged, compared to its average volume of 22,874. The company has a quick ratio of 2.13, a current ratio of 2.64 and a debt-to-equity ratio of 0.45. The business has a fifty day moving average price of $56.22 and a 200-day moving average price of $47.47. Kewaunee Scientific Co. has a fifty-two week low of $30.82 and a fifty-two week high of $71.33. The stock has a market capitalization of $113.69 million, a P/E ratio of 6.31 and a beta of 0.71.

Remove Ads

Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The technology company reported $1.09 earnings per share (EPS) for the quarter. The company had revenue of $67.17 million during the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Kewaunee Scientific from a "buy" rating to a "hold" rating in a research note on Friday, March 14th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Invesco Ltd. acquired a new stake in Kewaunee Scientific in the fourth quarter worth $6,545,000. Marshall Wace LLP bought a new position in Kewaunee Scientific in the fourth quarter valued at $736,000. De Lisle Partners LLP raised its holdings in Kewaunee Scientific by 36.6% during the third quarter. De Lisle Partners LLP now owns 42,958 shares of the technology company's stock worth $1,446,000 after acquiring an additional 11,511 shares in the last quarter. Truffle Hound Capital LLC acquired a new stake in shares of Kewaunee Scientific in the 4th quarter valued at approximately $619,000. Finally, State Street Corp bought a new position in shares of Kewaunee Scientific in the 3rd quarter valued at about $266,000. Institutional investors own 32.69% of the company's stock.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.